# Effectiveness of Multisymptom Support for Better Relief and Alleviation of Common Effects in Perimenopause (EMBRACE PERIMENOPAUSE)

## TL;DR

A study found that a nutraceutical capsule significantly reduced perimenopause symptoms like hot flashes and improved quality of life in women.

## Contribution

This study provides evidence that a nonhormonal nutraceutical is effective for managing perimenopause symptoms.

## Key findings

- The capsule reduced the Menopause Rating Scale score by 92.97% over 60 days.
- 93% of patients experienced complete resolution of hot flashes by day 60.
- Quality of life and patient satisfaction improved significantly with the treatment.

## Abstract

Background: Menopause affects 1.5 million women annually, with perimenopause lasting 2-8 years and causing symptoms like hot flashes, sleep disturbances, mood changes, and joint pain. While hormone replacement therapy (HRT) is effective, safety concerns limit its use, leading many women to seek nonhormonal alternatives. Nutraceuticals such as ashwagandha, vitex, and black cohosh offer potential benefits, with 80% of women using supplements. This study evaluates the efficacy and safety of Arth perimenopause multisymptom capsules, providing evidence for nutraceuticals as an alternative to HRT.

Methodology: The Effectiveness of Multisymptom Support for Better Relief and Alleviation of Common Effects in Perimenopause (EMBRACE PERIMENOPAUSE) study was a prospective, observational trial conducted at Redkar Hospital and Research Center, Goa. Thirty perimenopausal women aged 40-48 years with irregular menstrual cycles and at least two menopausal symptoms received one Arth capsule daily for 60 days. Using standardized case report forms, data were collected at screening, baseline, and days 7, 15, 30, and 60. Primary outcomes included changes in menopausal symptoms (Menopause Rating Scale (MRS)), reduction in daily hot flashes, and improvement in breast tenderness. Secondary outcomes assessed the quality of life (QoL), changes in hair and skin texture, patient and physician global assessments, and intervention tolerability. Statistical analyses included Chi-square tests and analysis of variance (ANOVA) (p < 0.05).

Results: At baseline, 100% of patients reported hot flashes, followed by irritability (90%) and night sweating (83%). The mean MRS score decreased from 39 at baseline to 2.74 by day 60 (-92.97%, p < 0.01). By day 60, 93% of patients achieved complete resolution of hot flashes, 88% for sweating, 91% for anxiety, and 90% for depressive mood (p < 0.05). Overall, treatment significantly improved menopausal symptoms, QoL, and patient satisfaction.

Conclusion: Arth Perimenopause Multisymptom Support capsules demonstrated significant efficacy in alleviating perimenopausal symptoms while improving QoL. This nonhormonal, well-tolerated nutraceutical represents a promising alternative for managing perimenopause-related discomfort.